Boehringer Ingelheim has started a registration trial of its experimental therapy brigimadlin as a treatment for dedifferentiated liposarcoma (DDLPS), a rare cancer with l
Regulators on both sides of the Atlantic have ruled that no new patients should start treatment with Eli Lilly’s Lartruvo (olaratumab) for soft tissue sarcoma, after a study that was suppos
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh